½ÃÀ庸°í¼­
»óǰÄÚµå
1362876

¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

U.S. External Counterpulsation Devices Market Size, Share & Trends Analysis Report By Product (Pneumatic ECP Devices, Electrocardiogram (ECG)-Synchronized), By End-use (Hospitals, Cardiac Centers), And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 100 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞÀü(ECP) ±â±â ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2¾ï 7,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È 7.6%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ºÀå ¿øµ¿·ÂÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿äÀ̸ç, ECP Ä¡·á´Â ºñħ½ÀÀû Ư¼º°ú Çù½ÉÁõ ¹× ½ÉºÎÀü µîÀÇ Áúȯ °ü¸®¿¡ ÀÖ¾î ÀÔÁõµÈ È¿°ú·Î ȯÀÚ ¹× ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üÀÇ Å« °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù.

°ü»óµ¿¸Æ ÁúȯÀÇ À¯º´·ü Áõ°¡, °ü»óµ¿¸Æ ȯÀÚÀÇ Á׻󵿸ưæÈ­Áõ Áõ°¡, Çù½ÉÁõ ¿¡ÇǼҵåÀÇ ±ÞÁõÀº ¿ÜºÎ ¹Úµ¿ ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Çù½ÉÁõ¿¡ ¼±ÇàÇÏ´Â °ü»óµ¿¸ÆÁúȯ ȯÀÚÀÇ ºñÀ²ÀÌ ³ô°í, Çù½ÉÁõ °ü¸®¸¦ À§ÇÑ ECP ±â±â äÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ ¿¹»óµÇ¸ç, 40¼¼ À̻󿡼­ ³ôÀº Á׻󵿸ưæÈ­Áõ ¹ß»ý·ü·Î ÀÎÇØ ÀÌ ¿¬·É´ëÀÇ 50%°¡ ½É°¢ÇÑ Á׻󵿸ưæÈ­ÁõÀ¸·Î ¹ßÀüÇÒ ¼ö ÀÖ½À´Ï´Ù. ECP Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

ü¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀåÀº ¾÷°èÀÇ ±â¼úÀû µµ¾à°ú Çõ½ÅÀ¸·Î ÀÎÇØ Å« ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº °í±Þ ¸ð´ÏÅ͸µ ±â´É, ¸ÂÃãÇü ¿É¼Ç ¹× ÀüÀÚ ÀÇ·á ±â·Ï ½Ã½ºÅÛ ÅëÇÕÀ» Ãß°¡ÇÏ¿© ECP ÀåÄ¡¸¦ Áö¼ÓÀûÀ¸·Î °­È­ÇÏ¿© ȯÀÚ °ü¸®, ¾ÈÀü¼º ¹× Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ »óȯ Á¤Ã¥ ¹× ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â Ŭ¸®´Ð°ú º´¿ø¿¡¼­ ECP ÀåºñÀÇ »ç¿ëÀ» ÃËÁøÇÏ¿© ½ÃÀåÀÇ »ó½Â¼¼¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå ³» ¸¹Àº °æÀï¾÷ü¿Í ÀϺΠ½ÉÀå Áúȯ Ä¡·á¿¡ ´ëÇÑ FDAÀÇ ½ÂÀÎÀº ¼¼°è ECP ±â±â ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

  • 2022³â¿¡´Â °ø¾Ð½Ä ECP ÀåÄ¡ ºÐ¾ß°¡ 35.68%ÀÇ ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ÀåÄ¡´Â °ø±â¾ÐÀ» »ç¿ëÇÏ¿© ½ÉÀåÀ¸·ÎÀÇ Ç÷·ù¸¦ °³¼±ÇÏ¿© Çù½ÉÁõ ¹× ³­Ä¡¼º Çù½ÉÁõ ȯÀÚÀÇ Áõ»óÀ» È¿°úÀûÀ¸·Î ¿ÏÈ­ÇÕ´Ï´Ù. ºñħ½ÀÀû Ư¼º, ºñ¿ë È¿À²¼º ¹× Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ȯÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿¡°Ô ¸Å·ÂÀûÀÔ´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÏ°í ½ÉÀ庴 ȯÀڵ鿡°Ô À¯¸ÁÇÑ Ä¡·á ¿É¼ÇÀÌ µÇ°í ÀÖ½À´Ï´Ù.
  • 2022³â¿¡´Â º´¿øÀÌ 35.68%ÀÇ Á¡À¯À²·Î ECP Àåºñ ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿øÀÇ ¸¹Àº ȯÀÚ ¼ö, ½ÉÇ÷°ü Áúȯ¿¡ ´ëÇÑ Àü¹®ÀûÀÎ Ä¡·á, °í±Þ ÀÚ¿ø°ú ±â¼ú¿¡ ´ëÇÑ Á¢±Ù¼º, Á¾ÇÕÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ÀÎÇØ º´¿øÀÌ ECP Ä¡·áÀÇ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü ÁúȯÀº Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, º´¿øÀÇ ECP Àåºñ¿¡ ´ëÇÑ ¼ö¿ä´Â ½ÃÀå Áö¹è·ÂÀ» ´õ¿í °­È­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷Àº Vaso Corporation, ACS Diagnostics, Scottcare Corporation, Cardiomedics Inc.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • 2022³â º¸±Þ°ú ¼ºÀå Àü¸Á ¸ÅÇÎ
  • »ç¾÷ ȯ°æ ºÐ¼®
    • SWOT ºÐ¼®;¿äÀκ°(Á¤Ä¡¡¤¹ý·ü, °æÁ¦¡¤±â¼ú)
    • PorterÀÇ Five Forces ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå : Á¦Ç° ºÎ¹® ºÐ¼®

  • ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå : ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • °ø±â¾Ð ECP ±â±â
  • ½ÉÀüµµ(ECG) µ¿±â ECP ±â±â
  • È®Àå ¿ÜºÎ Ä«¿îÅÍÆÞ¼¼À̼Ç(EECP) ±â±â

Á¦5Àå ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµ ºÎ¹® ºÐ¼®

  • ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â : ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â ¹× 2030³â
  • ½ÉÀå ÁßÃß
  • º´¿ø

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
  • ±â¾÷ °³¿ä/¸®½ºÆ® Ç¥
    • Vaso Corporation
    • ACS Diagnostics
    • Scottcare Corporation
    • Cardiomedics Inc
LSH 23.10.27

U.S. External Counterpulsation (ECP) Devices Market Growth & Trends:

The U.S. external counterpulsation (ECP) devices market size is expected to reach USD 272.5 million by 2030, growing at a CAGR of 7.6% during the forecast period, according to a new report by Grand View Research, Inc.. The growth is driven by the increasing prevalence of cardiovascular diseases and the demand for effective treatments. ECP therapy, known for its non-invasive nature and proven efficacy in managing conditions like angina pectoris and heart failure, has garnered significant interest from patients and healthcare providers.

The rise in the prevalence of coronary artery diseases, increase in atherosclerosis in coronary artery patients, and surge in angina episodes are projected to drive the external counterpulsation devices market's growth. With a significant proportion of coronary artery disease cases preceding angina and the rising adoption of ECP devices for managing angina, the market is expected to grow. The incidence of atherosclerosis, most common in patients above 40, further contributes to the demand for ECP therapy, as nearly 50% of individuals in this age group are likely to develop serious atherosclerosis conditions.

Significant growth has been seen in the market for external counterpulsation (ECP) devices, driven by technological breakthroughs and innovations in the industry. By adding advanced monitoring capabilities, customization choices, and electronic medical record system integration, manufacturers continuously enhance ECP devices, improving patient care, safety, and treatment outcomes. Positive reimbursement policies and regulatory frameworks promote the growing use of ECP devices in clinic and hospital settings, which adds to the market's upward trend. Additionally, significant competitors in the market and FDA clearance for treating several cardiac diseases are anticipated to fuel the expansion of the worldwide ECP devices market.

U.S. External Counterpulsation Devices Market Report Highlights:

  • In 2022, the pneumatic ECP devices segment held a dominant market share of 35.68%. These devices use air pressure to improve blood flow to the heart, effectively reducing symptoms in angina and refractory angina pectoris patients. Their non-invasive nature, cost-effectiveness, and ongoing technological advancements make them appealing to patients and healthcare providers. The rising prevalence of cardiovascular diseases further fuels the growth of this segment, making it a promising therapeutic option for cardiac patients
  • In 2022, hospitals dominated the ECP device market with a share of 35.68%. Their larger patient volumes, specialized care for cardiovascular diseases, access to advanced resources and technologies, and comprehensive treatment options make hospitals the preferred choice for ECP therapy. As cardiovascular diseases continue to rise, the demand for hospital ECP devices is expected to reinforce their market dominance
  • Some key market players are Vaso Corporation, ACS Diagnostics, Scottcare Corporation, and Cardiomedics Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information Or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Restraint Analysis
  • 3.6. Penetration And Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. U.S. External Counterpulsation (ECP) Devices Market: Product Segment Analysis

  • 4.1. U.S. External Counterpulsation (ECP) Devices Market: Market Share Analysis, 2022 & 2030
  • 4.2. Pneumatic ECP Devices
    • 4.2.1. Pneumatic ECP Devices Market, 2018 - 2030 (USD Million)
  • 4.3. Electrocardiogram (ECG)-Synchronized ECP Devices
    • 4.3.1. Electrocardiogram (ECG)-Synchronized ECP Devices Market, 2018 - 2030 (USD Million)
  • 4.4. Enhanced External Counterpulsation (EECP) Devices
    • 4.4.1. Enhanced External Counterpulsation (EECP) Devices Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. External Counterpulsation (ECP) Devices Market: End-Use Segment Analysis

  • 5.1. U.S. External Counterpulsation (ECP) Devices: Market Share Analysis, 2022 & 2030
  • 5.2. Cardiac Centers
    • 5.2.1. Cardiac Centers Market, 2018 - 2030 (USD Million)
  • 5.3. Hospitals
    • 5.3.1. Hospitals Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Vaso Corporation
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. ACS Diagnostics
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Scottcare Corporation
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Cardiomedics Inc
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦